Vir Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-04-07
- Employees
- 587
- Market Cap
- -
- Website
- http://www.vir.bio
- Introduction
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
Vir Biotechnology to host virtual investor event on January 8, 2025, discussing initial data from Phase 1 T-cell engager programs VIR-5818 (HER2-expressing solid tumors) and VIR-5500 (PSMA in mCRPC), along with updates on the PRO-XTEN™ platform. The event will be accessible via webcast and archived for 30 days.
SWOT analysis: stock poised for growth amid clinical progress
Vir Biotechnology, a clinical-stage immunology company, focuses on treating serious infectious diseases, particularly hepatitis delta virus (HDV) and hepatitis B virus (HBV). Recent positive Phase 2 data for HDV and HBV treatments have advanced the HDV program to Phase 3 trials. Despite negative earnings per share projections, Vir's strong balance sheet supports long-term growth. The company's strategic partnerships and pipeline expansion into T-cell engagers offer potential market opportunities, though clinical trial risks and commercialization challenges remain.
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Vir Biotechnology Inc. announced Marianne De Backer will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Dec 3, 6:10 a.m. PT / 9:10 a.m. ET in Miami, with a live webcast available on the Vir Biotechnology website.
Vir Biotechnology CEO to Present at Evercore ISI HealthCONx Conference
Vir Biotechnology's CEO Marianne De Backer will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference in Miami, Florida, on December 3 at 6:10 a.m. PT / 9:10 a.m. ET. A live webcast will be available on the company's website and accessible for 30 days.
© Copyright 2024. All Rights Reserved by MedPath